


What is claimed is:

1. A bispecific antigen-binding molecule comprising:
a first antigen-binding domain (D1) comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138; and
a second antigen-binding domain (D2) comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 82 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138;
wherein D1 specifically binds a first epitope of human MET; and wherein D2 specifically binds a second epitope of human MET.
2. The bispecific antigen-binding molecule of claim 1, wherein the bispecific antigen-binding molecule is conjugated to a cytotoxin.
3. The bispecific antigen-binding molecule of claim 2, wherein the cytotoxin is selected from the group consisting of biotoxins, chemotherapeutic agents, and radioisotopes.
4. The bispecific antigen-binding molecule of claim 2, wherein the cytotoxin is selected from the group consisting of maytansinoids, auristatins, duocarmycins, ²²⁵Ac, ²²⁷Th, and any derivatives thereof and any derivatives thereof.
5. The bispecific antigen-binding molecule of claim 1, wherein the bispecific antigen-binding molecule is conjugated to a cytotoxic agent through a linker.
6. The bispecific antigen-binding molecule of claim 5, wherein the cytotoxic agent is a maytansinoid.
7. The bispecific antigen-binding molecule of claim 6, wherein the maytansinoid is:





wherein the



is the bond to the linker.

8. The bispecific antigen-binding molecule of claim 7, wherein the linker is:





wherein the bond noted with




represents the bond to the bispecific antigen-binding molecule and the bond noted with



represents the bond to the maytansinoid.

9. The bispecific antigen-binding molecule of claim 6, wherein the maytansinoid is




wherein the



is the bond to the linker.

10. The bispecific antigen-binding molecule of claim 9, wherein the linker is:



wherein the bond noted with



represents the bond to the bispecific antigen-binding molecule and the bond noted with



represents the bond to the maytansinoid.

11. A pharmaceutical composition comprising the bispecific antigen-binding molecule of claim 1, and a pharmaceutically acceptable carrier.

12. A bispecific antigen-binding molecule comprising:

a first antigen-binding domain D1 comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:60;

HCDR2 comprising the amino acid sequence of SEQ ID NO:62; HCDR3 comprising the amino acid sequence of SEQ ID NO:64;

LCDR1 comprising the amino acid sequence of SEQ ID NO:140; LCDR2 comprising the amino acid sequence of SEQ ID NO:142; and

LCDR3 comprising the amino acid sequence of SEQ ID NO:144; wherein D1 specifically binds a first epitope of human MET; and

a second antigen-binding domain D2 comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84;

an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86;

an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88;

an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140;

an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and

an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144; wherein D2 specifically binds a second epitope of human MET.

13. The bispecific antigen-binding molecule of claim 12, wherein D1 comprises:


an HCVR comprising the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence that is at least 95% identical thereto; and

an LCVR comprising the amino acid sequence of SEQ ID NO: 138 or an amino acid sequence that is at least 95% identical thereto.


14. The bispecific antigen-binding molecule of claim 13, wherein D1 comprises:

an HCVR comprising the amino acid sequence of SEQ ID NO: 58; and
an LCVR comprising the amino acid sequence of SEQ ID NO: 138.

15. The bispecific antigen-binding molecule of claim 12, wherein D2 comprises:
an HCVR comprising the amino acid sequence of SEQ ID NO: 82 or
an amino acid sequence that is at least 95% identical thereto; and
an LCVR comprising the amino acid sequence of SEQ ID NO: 138 or an amino acid
sequence that is at least 95% identical thereto.
16. The bispecific antigen-binding molecule of claim 15, wherein D2 comprises:
an HCVR comprising the amino acid sequence of SEQ ID NO: 82; and an LCVR
comprising the amino acid sequence of SEQ ID NO: 138.
17. The bispecific antigen-binding molecule of claim 12, wherein the bispecific antigen-
binding molecule is conjugated to a maytansinoid through a linker, and wherein the
maytansinoid is




wherein the



is the bond to the linker.

18. The bispecific antigen-binding molecule of claim 17, wherein the linker is:



wherein the bond noted with



represents the bond to the bispecific antigen-binding molecule and the bond noted with



represents the bond to the maytansinoid.

19. The bispecific antigen-binding molecule of claim 18, wherein:

D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 58 and an LCVR comprising the amino acid sequence of SEQ ID NO: 138; and


D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 82; and an LCVR comprising the amino acid sequence of SEQ ID NO: 138.

20. A method for preparing an antibody-drug conjugate comprising contacting:

(a) an anti-MET antibody comprising the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138; or

(b) a METxMET bispecific antigen-binding protein comprising: a first antigen binding domain D1 comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138, wherein D1 specifically binds a first epitope of human MET and a second antigen binding domain D2 comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 82 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138 wherein D2 specifically binds a second epitope of human MET, with a compound having the following formula A¹:


A¹



and aqueous diluent.


21. An antibody-drug conjugate prepared by the process of: (i) contacting a compound of formula (a):

(a)



with a compound of formula (b):

(b)



in the presence of silica gel and diluent to synthesize an intermediate; and

(ii) contacting:

(a) an anti-MET antibody comprising the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:138; or

(b) a METxMET bispecific antigen-binding protein comprising:

a first antigen binding domain D1 comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 58 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138, wherein D1 specifically binds a first epitope of human MET, and a second antigen binding domain D2 comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 82 and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 138 wherein D2 specifically binds a second epitope of human MET, with the intermediate and aqueous diluent.

22. A bispecific antigen-binding molecule comprising:

a first antigen binding domain D1 comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:20;

HCDR2 comprising the amino acid sequence of SEQ ID NO:22;
HCDR3 comprising the amino acid sequence of SEQ ID NO:24;
LCDR1 comprising the amino acid sequence of SEQ ID NO:140;
LCDR2 comprising the amino acid sequence of SEQ ID NO:142; and
LCDR3 comprising the amino acid sequence of SEQ ID NO:144;
wherein D1 specifically binds a first epitope of human MET; and
a second antigen binding domain D2 comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84;
an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86;
an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88;
an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140;
an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and
an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144; wherein D2 specifically binds a second epitope of human MET.

23. The bispecific antigen-binding molecule of claim 22, wherein:
D1 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 18 and
an LCVR comprising the amino acid sequence of SEQ ID NO: 138; and
D2 comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 82; and
an LCVR comprising the amino acid sequence of SEQ ID NO: 138.

24. A bispecific antigen-binding molecule comprising:
a first antigen-binding domain (D1) wherein D1 specifically binds a first epitope of human MET; and
a second antigen-binding domain (D2) wherein D2 specifically binds a second epitope of human MET; and
wherein D1 comprises the CDRs within the D1-HCVR amino acid sequence of SEQ ID NO: 18 and the CDRs within the D1-LCVR amino acid sequence of SEQ ID NO: 138, and
D2 comprises the CDRs within the D2-HCVR amino acid sequence of SEQ ID NO: 82 and the D2-LCVR amino acid sequence of SEQ ID NO: 138.